PUBLIC CONTRACT · 2025
4180447/2025-ocrelizumab 920MG (40 mg/ml AMP 23ML) sol inj - Procedimento até final do ano
- Contract value
- €9,459.09
- Signed on
- 22 November 2025
- Procedure
- Ao abrigo de acordo-quadro (art.º 258.º)
This page lays out the fields published on Portal BASE and says when a field is unavailable. It is not an assessment of the contract's merit, legality or impact.
Record 13657500PUBLISHED SUBJECT
4180447/2025-OCRELIZUMAB 920MG (40 MG/ML AMP 23ML) SOL INJ - PROCEDIMENTO ATÉ FINAL DO ANO
Parties involved
- Place of performance
- Portugal, Setúbal, Barreiro
- NUTS region
- Not stated
WHO BID
Awardee and competitors
Companies that IMPIC lists as the awardee and as competitors in this procedure.
- Awardee
- ROCHE FARMACEUTICA QUIMICA, LDA · Tax ID 500233810
Values and timeline
- Contract price
- €9,459.09
- Procedure base price
- €9,459.09
- Total effective price
- €9,459.09
- Publication date
- 25 February 2026
- Award date
- 21 November 2025
- Signing date
- 22 November 2025
- Performance period
- 365 days
The contract price is the value agreed in the contract, not the amount paid.
Procedure and framework
- Contract type
- Aquisição de bens móveis
- Procedure type
- Ao abrigo de acordo-quadro (art.º 258.º)
- Award criterion
- Monofator
- CPV code
- 33600000-6 - Produtos farmacêuticos
- Legal basis
- Artigo 31.º, n.º 3 do Código dos Contratos Públicos
- Regime
- Código dos Contratos Públicos ( DL 111-B/2017 )
- Framework agreement
- 1303/2025 - Concurso público internacional para formação do acordo quadro de medicamentos diversos na área da saúde
- Centralised procedure
- No
- Environmental criterion
- No
- Notice
- Not stated
- Procedure identifier
- 9700458
Compare with other contracts
Search the same body, supplier, place or type of service to understand the context of the published index.